Joseph Wolk, Chief Financial Officer of Johnson & Johnson, on reallocating a global healthcare company’s resources to create a COVID-19 vaccine.
Joseph Wolk, Chief Financial Officer of Johnson & Johnson, discusses key aspects of the company’s strategic shift toward developing a COVID-19 vaccine.
From the moment Johnson & Johnson executives learned of the virus, to the ultimate decision to enter into the race to eradicate the global pandemic, Wolk goes behind the scenes of what it’s like to be a key decision-maker in one of the largest international medical companies. He also offers insight into how corporate values should drive decision-making during a crisis—even during a global pandemic.